CN102085368B - 优化的TACI-Fc融合蛋白用于制备治疗系统性红斑狼疮药物的应用 - Google Patents
优化的TACI-Fc融合蛋白用于制备治疗系统性红斑狼疮药物的应用 Download PDFInfo
- Publication number
- CN102085368B CN102085368B CN 201110021344 CN201110021344A CN102085368B CN 102085368 B CN102085368 B CN 102085368B CN 201110021344 CN201110021344 CN 201110021344 CN 201110021344 A CN201110021344 A CN 201110021344A CN 102085368 B CN102085368 B CN 102085368B
- Authority
- CN
- China
- Prior art keywords
- rct
- sle
- taci
- mice
- marrow
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000000596 systemic lupus erythematosus Diseases 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 239000003814 drug Substances 0.000 title abstract description 33
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 title abstract description 28
- 108020001507 fusion proteins Proteins 0.000 title abstract description 4
- 102000037865 fusion proteins Human genes 0.000 title abstract description 4
- 101710178302 Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 title abstract 4
- 230000004927 fusion Effects 0.000 claims description 31
- 238000005457 optimization Methods 0.000 claims description 15
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 abstract description 82
- 238000011282 treatment Methods 0.000 abstract description 9
- 208000023275 Autoimmune disease Diseases 0.000 abstract description 7
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 210000001185 bone marrow Anatomy 0.000 description 61
- 241000699670 Mus sp. Species 0.000 description 60
- 230000000694 effects Effects 0.000 description 38
- 230000014509 gene expression Effects 0.000 description 38
- 210000000952 spleen Anatomy 0.000 description 35
- 238000010254 subcutaneous injection Methods 0.000 description 33
- 239000007929 subcutaneous injection Substances 0.000 description 33
- 241000699666 Mus <mouse, genus> Species 0.000 description 26
- 241001465754 Metazoa Species 0.000 description 25
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 description 24
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 21
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 21
- 238000000034 method Methods 0.000 description 20
- 210000002966 serum Anatomy 0.000 description 19
- 230000004913 activation Effects 0.000 description 18
- 241000700159 Rattus Species 0.000 description 17
- 210000001165 lymph node Anatomy 0.000 description 16
- 229940079593 drug Drugs 0.000 description 14
- 210000002700 urine Anatomy 0.000 description 14
- 108010077544 Chromatin Proteins 0.000 description 13
- 210000003483 chromatin Anatomy 0.000 description 13
- 230000029142 excretion Effects 0.000 description 13
- 238000010172 mouse model Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 102000003814 Interleukin-10 Human genes 0.000 description 12
- 108090000174 Interleukin-10 Proteins 0.000 description 12
- 108700002718 TACI receptor-IgG Fc fragment fusion Proteins 0.000 description 12
- 229940076144 interleukin-10 Drugs 0.000 description 12
- 229950009925 atacicept Drugs 0.000 description 11
- 210000002381 plasma Anatomy 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 10
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 description 10
- 210000003719 b-lymphocyte Anatomy 0.000 description 10
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical group CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 9
- 108060003951 Immunoglobulin Proteins 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 210000003608 fece Anatomy 0.000 description 9
- 102000018358 immunoglobulin Human genes 0.000 description 9
- 210000003734 kidney Anatomy 0.000 description 9
- 210000001541 thymus gland Anatomy 0.000 description 9
- 102100037850 Interferon gamma Human genes 0.000 description 8
- 108010074328 Interferon-gamma Proteins 0.000 description 8
- 101710178300 Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 230000006870 function Effects 0.000 description 7
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 6
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 6
- 241000699660 Mus musculus Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 238000011830 transgenic mouse model Methods 0.000 description 6
- 206010001580 Albuminuria Diseases 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 210000000941 bile Anatomy 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000036285 pathological change Effects 0.000 description 5
- 231100000915 pathological change Toxicity 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 208000002874 Acne Vulgaris Diseases 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 4
- 206010018364 Glomerulonephritis Diseases 0.000 description 4
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 4
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 4
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 4
- 230000006044 T cell activation Effects 0.000 description 4
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 4
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 4
- 206010000496 acne Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000000857 drug effect Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 206010020718 hyperplasia Diseases 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000003907 kidney function Effects 0.000 description 4
- 206010025135 lupus erythematosus Diseases 0.000 description 4
- 230000010534 mechanism of action Effects 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 230000000770 proinflammatory effect Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000003393 splenic effect Effects 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 201000004384 Alopecia Diseases 0.000 description 3
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 3
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 3
- 238000011725 BALB/c mouse Methods 0.000 description 3
- 102100027207 CD27 antigen Human genes 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 108010087819 Fc receptors Proteins 0.000 description 3
- 102000009109 Fc receptors Human genes 0.000 description 3
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 3
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 3
- 206010020880 Hypertrophy Diseases 0.000 description 3
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 3
- 231100000360 alopecia Toxicity 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 102000006834 complement receptors Human genes 0.000 description 3
- 108010047295 complement receptors Proteins 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000000155 isotopic effect Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000700 radioactive tracer Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 102100032937 CD40 ligand Human genes 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 2
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 108700002109 Transmembrane Activator and CAML Interactor Proteins 0.000 description 2
- 102000050862 Transmembrane Activator and CAML Interactor Human genes 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002547 anomalous effect Effects 0.000 description 2
- 230000003460 anti-nuclear Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000003851 biochemical process Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000001280 germinal center Anatomy 0.000 description 2
- 210000002149 gonad Anatomy 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000000527 lymphocytic effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 210000003519 mature b lymphocyte Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000001806 memory b lymphocyte Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000000575 pesticide Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 206010049865 Achromotrichia acquired Diseases 0.000 description 1
- 208000020154 Acnes Diseases 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 108010046304 B-Cell Activation Factor Receptor Proteins 0.000 description 1
- 102100021568 B-cell scaffold protein with ankyrin repeats Human genes 0.000 description 1
- 108700031361 Brachyury Proteins 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- 102000001493 Cyclophilins Human genes 0.000 description 1
- 108010068682 Cyclophilins Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 101000971155 Homo sapiens B-cell scaffold protein with ankyrin repeats Proteins 0.000 description 1
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102100033467 L-selectin Human genes 0.000 description 1
- 208000005777 Lupus Nephritis Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- -1 absorption carrier Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 210000003297 immature b lymphocyte Anatomy 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 201000006334 interstitial nephritis Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000007119 pathological manifestation Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000003720 plasmablast Anatomy 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960002800 prednisolone acetate Drugs 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110021344 CN102085368B (zh) | 2011-01-19 | 2011-01-19 | 优化的TACI-Fc融合蛋白用于制备治疗系统性红斑狼疮药物的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110021344 CN102085368B (zh) | 2011-01-19 | 2011-01-19 | 优化的TACI-Fc融合蛋白用于制备治疗系统性红斑狼疮药物的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102085368A CN102085368A (zh) | 2011-06-08 |
CN102085368B true CN102085368B (zh) | 2013-06-12 |
Family
ID=44097529
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201110021344 Active CN102085368B (zh) | 2011-01-19 | 2011-01-19 | 优化的TACI-Fc融合蛋白用于制备治疗系统性红斑狼疮药物的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102085368B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3868403A4 (en) * | 2019-12-24 | 2022-04-06 | RemeGen Co., Ltd. | TACI-FC FUSION PROTEIN AND USE THEREOF |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2020401160A1 (en) | 2019-12-10 | 2021-08-19 | Remegen Co., Ltd. | Pharmaceutical TACI-Fc fusion protein formulation |
PE20230494A1 (es) | 2020-05-08 | 2023-03-23 | Alpine Immune Sciences Inc | Proteinas inmunomoduladoras inhibidoras de april y baff y metodos de uso de las mismas |
WO2023051660A1 (zh) * | 2021-09-30 | 2023-04-06 | 荣昌生物制药(烟台)股份有限公司 | 用TACI-Fc融合蛋白治疗干燥综合征的方法 |
CA3236667A1 (en) * | 2022-06-08 | 2023-12-14 | Jianmin Fang | Method for treating myasthenia gravis with taci-fc fusion protein |
CN115281152B (zh) * | 2022-08-12 | 2024-03-12 | 浙江中医药大学 | 一种小鼠狼疮脑病模型的构建方法 |
AU2023387777A1 (en) * | 2022-12-07 | 2024-08-29 | Remegen Co., Ltd. | Taci-fc fusion protein liquid pharmaceutical preparation |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101323643A (zh) * | 2007-06-15 | 2008-12-17 | 烟台荣昌生物工程有限公司 | 优化的TACI-Fc融合蛋白 |
-
2011
- 2011-01-19 CN CN 201110021344 patent/CN102085368B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101323643A (zh) * | 2007-06-15 | 2008-12-17 | 烟台荣昌生物工程有限公司 | 优化的TACI-Fc融合蛋白 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3868403A4 (en) * | 2019-12-24 | 2022-04-06 | RemeGen Co., Ltd. | TACI-FC FUSION PROTEIN AND USE THEREOF |
Also Published As
Publication number | Publication date |
---|---|
CN102085368A (zh) | 2011-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102085368B (zh) | 优化的TACI-Fc融合蛋白用于制备治疗系统性红斑狼疮药物的应用 | |
McIntyre et al. | Transforming growth factor beta 1 selectivity stimulates immunoglobulin G2b secretion by lipopolysaccharide-activated murine B cells. | |
US7214658B2 (en) | Method of delivering a TNF antagonist to the brain of a human by perispinal administration without direct intrathecal injection | |
Arend | The mode of action of cytokine inhibitors. | |
CN102085367B (zh) | 优化的TACI-Fc融合蛋白用于制备治疗类风湿性关节炎药物的应用 | |
Kent et al. | Mechanisms of sickness-induced decreases in food-motivated behavior | |
CN103079586B (zh) | G‑csf二聚体在治疗嗜中性粒细胞减少症中的应用 | |
CN101415403A (zh) | 药物制剂的固体口服剂形式及其制备方法 | |
Ju et al. | Oral administration of type-II collagen suppresses IL-17-associated RANKL expression of CD4+ T cells in collagen-induced arthritis | |
Frendl | Interleukin 3: from colony-stimulating factor to pluripotent immunoregulatory cytokine | |
CN106539814A (zh) | 干扰素基因刺激蛋白(sting)激动剂在抗类风湿性关节炎等疾病中的应用 | |
WO1998051344A1 (en) | Suppression of tumor necrosis factor alpha and vascular endothelial growth factor in therapy | |
CN102010473A (zh) | 重组胃泌酸调节素融合蛋白及其制备和应用 | |
Elliott et al. | TNFα blockade in rheumatoid arthritis: Rationale, clinical outcomes and mechanisms of action | |
WO2021128027A1 (zh) | TACI-Fc融合蛋白及其用途 | |
Zuany-Amorim et al. | Induction of TNF-α autoantibody production by AutoVac TNF106: a novel therapeutic approach for the treatment of allergic diseases | |
Nikam et al. | Current and emerging prospects in the psoriatic treatment | |
US5932427A (en) | In vitro assay system for identifying compositions useful for stimulating B cells | |
KR101986774B1 (ko) | 과면역 반응에 의해 유발되는 염증성 질환 치료용 조성물 | |
Ayoub et al. | Modulation of the Th1/Th2 bias by an immunoglobulin histamine complex in the ovalbumin allergy mouse model | |
Song et al. | Effects of Inula britannica on the production of antibodies and cytokines and on T cell differentiation in C57BL/6 mice immunized by ovalbumin | |
Chowers et al. | Efficacy of anti-TNF in Crohn's disease: how does it work? | |
CA3230014A1 (en) | Fusion protein of interleukin-2 and application thereof in ibd | |
CN1274364C (zh) | 抗FcεRIα单克隆抗体Fab片段与雷公藤红素的交联体 | |
Yu et al. | Effect of Fuzheng Jiedu granule on immunological function and level of immune-related cytokines in immune-suppressed mice |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Yantai Rongchang Pharmaceutical Co., Ltd. Assignor: Rongchang Biological Engineering Co., Ltd., Yantai Contract record no.: 2011370000432 Denomination of invention: Application of optimized TACI (Transmembrane Activator and CAML Interactor)-Fc fusion protein in preparation of medicaments for treating systemic lupus erythematosus License type: Common License Open date: 20110608 Record date: 20110923 |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EM01 | Change of recordation of patent licensing contract |
Change date: 20131205 Contract record no.: 2011370000432 Assignee after: Yantai Rongchang Pharmacy Co., Ltd. Assignee before: Yantai Rongchang Pharmaceutical Co., Ltd. |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
EM01 | Change of recordation of patent licensing contract |
Change date: 20131205 Contract record no.: 2011370000432 Assignee after: Yantai Rongchang Pharmacy Co., Ltd. Assignee before: Yantai Rongchang Pharmaceutical Co., Ltd. |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: 264006 Yantai economic and Technological Development Zone, Beijing, No. 58 Middle Road, Shandong Patentee after: Rongchang Biological Engineering Co., Ltd., Yantai Address before: 264006 No. 1, Rongchang Road, Yantai economic and Technological Development Zone, Shandong Patentee before: Rongchang Biological Engineering Co., Ltd., Yantai |
|
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 264006 Yantai economic and Technological Development Zone, Beijing, No. 58 Middle Road, Shandong Patentee after: Rongchang bio Pharmaceutical (Yantai) Co., Ltd. Address before: 264006 Yantai economic and Technological Development Zone, Beijing, No. 58 Middle Road, Shandong Patentee before: Rongchang Biological Engineering Co., Ltd., Yantai |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170414 Address after: 264006 Yantai economic and Technological Development Zone, Beijing, No. 58 Middle Road, Shandong Patentee after: Yantai Rongchang Pharmacy Co., Ltd. Address before: 264006 Yantai economic and Technological Development Zone, Beijing, No. 58 Middle Road, Shandong Patentee before: Rongchang bio Pharmaceutical (Yantai) Co., Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190801 Address after: 264006 Yantai economic and Technological Development Zone, Beijing, No. 58 Middle Road, Shandong Patentee after: Rongchang bio Pharmaceutical (Yantai) Co., Ltd. Address before: 264006 Yantai economic and Technological Development Zone, Beijing, No. 58 Middle Road, Shandong Patentee before: Yantai Rongchang Pharmacy Co., Ltd. |
|
EC01 | Cancellation of recordation of patent licensing contract | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Yantai Rongchang Pharmacy Co., Ltd. Assignor: Rongchang Biopharmaceutical (Yantai) Co., Ltd. Contract record no.: 2011370000432 Date of cancellation: 20191104 |
|
EM01 | Change of recordation of patent licensing contract | ||
EM01 | Change of recordation of patent licensing contract |
Change date: 20191104 Contract record no.: 2011370000432 Assignor after: Rongchang Biopharmaceutical (Yantai) Co., Ltd. Assignor before: Rongchang Biological Engineering Co., Ltd., Yantai |